EUVIMEDEUVIMED entdecken
Fallbericht

A case of herpetiform pemphigus mimicking bullous pemphigoid after using secukinumab and successfully treated with sulfasalazine

Rui Wang, Mingyue Wang iD

The Journal of Dermatology · 2023

DOI: 10.1111/1346-8138.16936 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Rui Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Pemphigus, Psoriasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin 17A (IL‐17A) inhibitors, such as secukinumab, have been widely used as the mainstream treatment for chronic plaque psoriasis; however, cutaneous adverse events have been reported. Here, we report a 43‐year‐old Chinese man who developed herpetiform pemphigus (HP) during secukinumab treatment for his psoriasis. He presented with (1) clinical features of HP, which resembled bullous pemphigoid; histopathological features of intraepidermal blisters, eosinophilic/neutrophilic spongiosis, and liquefactive degeneration of the basal cell layer; (3) positive anti‐desmoglein 1 antibody by enzyme‐linked immunosorbent assay and cell surface IgG reactivity within the epidermis by indirect immunofluorescence assay; and (4) a satisfactory response to salicylazosulfapyridine (sulfasalazine). To the best of our knowledge, this is the first report of the development of HP after the use of secukinumab for psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousPemphigusPsoriasisAdultHumansMaleSulfasalazineAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

IL-17A inhibitorherpetiform pemphiguspsoriasissecukinumabsulfasalazine

Substanzen

SulfasalazinesecukinumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Peking University First Hospital, Beijing, China.
  • National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
  • Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.
  • NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China.

ORCID-Profile: Mingyue Wang

Zitieren

APA

Wang, R., & Wang, M. (2023). A case of herpetiform pemphigus mimicking bullous pemphigoid after using secukinumab and successfully treated with sulfasalazine. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16936

Vancouver

Wang R, Wang M. A case of herpetiform pemphigus mimicking bullous pemphigoid after using secukinumab and successfully treated with sulfasalazine. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16936

BibTeX
@article{Wang2023,
  author = {Wang, Rui and Wang, Mingyue},
  title = {A case of herpetiform pemphigus mimicking bullous pemphigoid after using secukinumab and successfully treated with sulfasalazine},
  journal = {The Journal of Dermatology},
  year = {2023},
  doi = {10.1111/1346-8138.16936}
}
Kostenlos starten →